142186-36-5

Usage

Chemical Properties

white powder

InChI:InChI=1/C13H16FNO4/c1-13(2,3)19-12(18)15-10(11(16)17)8-4-6-9(14)7-5-8/h4-7,10H,1-3H3,(H,15,18)(H,16,17)/p-1/t10-/m0/s1

Upstream product

• 124-38-9 carbon dioxide 
• 196707-30-9 N-(trimethylsilyl)-N-(tert-butyloxycarbonyl)-4-fluorobenzylamine 
• 153903-23-2 (4-fluorobenzyl)carbamic acid tert-butyl ester 
• 1021948-11-7 C₁₅H₂₀FNO₃S 
• 140-75-0 para-fluorobenzylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 19883-57-9 (S)-2-amino-2-(4-fluorophenyl)acetic acid 

Downstream Products

• 956000-05-8 (S)-N-(tert-butoxycarbonyl)-(4-fluorophenyl)glycinamide 
• 1266230-73-2 tert-butyl [(1S)-2-[(3S,7R,8aR)-3-[(4R)-3,4-dihydro-2H-chromen-4-ylcarbamoyl]-7-ethoxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-1-(4-fluorophenyl)-2-oxoethyl]carbamate 
• 680231-52-1 tert-butyl ((1S)-1-(4-fluorophenyl)-2-oxo-2-{(2R,3S)-[4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}ethyl) carbamate 
• 903897-76-7 2-amino-N-(3,5-bis-trifluoromethyl-benzyl)-2-(4-fluoro-phenyl)-acetamide 
• 956001-37-9 (S)-tert-butyl (cyano(4-fluorophenyl)methyl)carbamate 
• 785041-04-5 (αS)-α-amino-4-fluoro-benzeneacetamide 

Relevant academic research and scientific papers

Amide derivative and application thereof

The invention relates to the field of chemical medicines, in particular to an amide derivative and application thereof. The amide derivative disclosed by the invention is shown I as a compound shown in the specification, and acts on 5 - HT. 2A

INDANE DERIVATIVES AS MGLUR7 MODULATORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds of formula (I) are mGluR7 modulators.

Chemo-enzymatic dynamic kinetic resolution of amino acid thioesters

The L-forms of racemic-N-protected-β,γa,aunsaturated a-amino acid thioesters were found to be substrates for the subtilisin-catalysed hydrolysis to the corresponding acids. The D-enantiomer was continuously racemised in the presence of an organic base. The combined reactions in a biphasic system allowed the deracemisation of the amino acid derivatives based on a dynamic kinetic resolution. Excellent yields and enantioselectivities were achieved.

Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study

A novel series of thiazolone-acylsulfonamides were designed as HCV NS5B polymerase allosteric inhibitors. The structure based drug designs (SBDD) were guided by docking results that revealed the potential to explore an additional pocket in the allosteric site. In particular, the designed molecules contain moieties of previously described thiazolone and a newly designed acylsulfonamide linker that is in turn connected with a substituted aromatic ring. The selected compounds were synthesized and demonstrated low μM activity. The X-ray complex structure was determined at a 2.2 A resolution and converged with the SBDD principle.

Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure

Structure-activity relationships (SAR) of 1 against HCV NS5B polymerase were described. SAR explorations and further structure-based design led to the identifications of 2 and 3 as novel HCV NS5B inhibitors. X-ray structure of 3 in complex with NS5B polymerase was obtained at a resolution of 2.2 A, and confirmed the design.

SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS

The present invention relates to substituted phenylcyclohexanecaboxamides of the formula (I), to processes for their preparation and to their use in medicaments, in particular for treating cardiovascular disorders.

Rapid access to N-Boc phenylglycine derivatives via benzylic lithiation reactions

We report a novel and efficient method for the enantioselective synthesis of N-Boc protected phenylglycines. Yields and enantiomeric ratios vary widely depending on the nature of the solvent, the substrate and on the method of forming the chiral complex. Results show that the major reaction pathway is an enantioselective deprotonation/substitution process. The enantioselectivity appears to be limited by the chiral discrimination ability of the s-BuLi-(-)-sparteine complex. The synthetic method described is one of the shortest route to useful enantioenriched N-Boc phenylglycine derivatives.

Enantioselective synthesis of phenylglycines using (-) sparteines·s-BuLi complex

The enantioselective synthesis of N-t-Boc protected phenylglycine derivatives is reported. The synthetic strategy involved the enantioselective deprotonation of N-t-Boc-N-TMS protected benzylamines using the (-) sparteine·s-BuLi complex.